This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abruzzo, G. K.
Right arrow Articles by Rosen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abruzzo, G. K.
Right arrow Articles by Rosen, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2310-2318, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice

George K. Abruzzo,1,* Charles J. Gill,1 Amy M. Flattery,1 Li Kong,1 Claire Leighton,1 Jeffrey G. Smith,2 V. Bill Pikounis,3 Ken Bartizal,4 and Hugh Rosen1

Infectious Diseases,1 Virus and Cell Biology,2 Biometrics Research,3 and Animal Health,4 Merck Research Laboratories, Rahway, New Jersey 07065-0900

Received 12 November 1999/Returned for modification 30 March 2000/Accepted 12 June 2000

The in vivo efficacy of the echinocandin antifungal caspofungin acetate (caspofungin; MK-0991) was evaluated in models of disseminated aspergillosis and candidiasis in mice with cyclophosphamide (CY)-induced immunosuppression. Caspofungin is a 1,3-beta -D-glucan synthesis inhibitor efficacious against a number of clinically relevant fungi including Aspergillus and Candida species. Models of CY-induced transient or chronic leukopenia were used with once daily administration of therapy initiated 24 h after microbial challenge. Caspofungin was effective in treating disseminated aspergillosis in mice that were transiently leukopenic (significant prolongation of survival at doses of >= 0.125 mg/kg of body weight and a 50% protective dose [PD50] of 0.245 mg/kg/day at 28 days after challenge) or chronically leukopenic (50 to 100% survival at doses of >= 0.5 mg/kg and PD50s ranging from 0.173 to 0.400 mg/kg/day). Caspofungin was effective in the treatment and sterilization of Candida infections in mice with transient leukopenia with a 99% effective dose based on reduction in log10 CFU of Candida albicans/gram of kidneys of 0.119 mg/kg and 80 to 100% of the caspofungin-treated mice having sterile kidneys at caspofungin doses from 0.25 to 2.0 mg/kg. In Candida-infected mice with chronic leukopenia, caspofungin was effective at all dose levels tested (0.25 to 1.0 mg/kg), with the log10 CFU of C. albicans/gram of kidneys of caspofungin-treated mice being significantly lower (>99% reduction) than that of sham-treated mice from day 4 to day 28 after challenge. Also, 70 to 100% of the caspofungin-treated, chronic leukopenic mice had sterile kidneys at caspofungin doses of 0.5 to 1.0 mg/kg from day 8 to 28 after challenge. Sterilization of Candida infections by caspofungin in the absence of host leukocytes provides compelling in vivo evidence for fungicidal activity against C. albicans. Further human clinical trials with caspofungin against serious fungal infections are in progress.

* Corresponding author. Mailing address: Infectious Diseases (RY80T-100), Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065-0900. Phone: (732) 594-6263. Fax: (732) 594-5700. E-mail: george_abruzzo{at}merck.com.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2310-2318, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Zhang, W., Nardi, M. A., Borkowsky, W., Li, Z., Karpatkin, S. (2009). Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 113: 4086-4093 [Abstract] [Full Text]  
  • van de Sande, W. W. J., van Vianen, W., ten Kate, M. T., Vissers, J., Laurijsens, J., Tavakol, M., Rijnders, B. J. A., Mathot, R. A. A., Bakker-Woudenberg, I. A. J. M. (2008). Caspofungin Prolongs Survival of Transiently Neutropenic Rats with Advanced-Stage Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 52: 1345-1350 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., Walsh, T. J. (2007). Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species. Antimicrob. Agents Chemother. 51: 881-887 [Abstract] [Full Text]  
  • Bowman, J. C., Abruzzo, G. K., Flattery, A. M., Gill, C. J., Hickey, E. J., Hsu, M. J., Nielsen Kahn, J., Liberator, P. A., Misura, A. S., Pelak, B. A., Wang, T. C., Douglas, C. M. (2006). Efficacy of Caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob. Agents Chemother. 50: 4202-4205 [Abstract] [Full Text]  
  • Cacciapuoti, A., Halpern, J., Mendrick, C., Norris, C., Patel, R., Loebenberg, D. (2006). Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus Infection.. Antimicrob. Agents Chemother. 50: 2587-2590 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2006). Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.. Antimicrob. Agents Chemother. 50: 1293-1297 [Abstract] [Full Text]  
  • van Vianen, W., de Marie, S., ten Kate, M. T., Mathot, R. A. A., Bakker-Woudenberg, I. A. J. M. (2006). Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 57: 732-740 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2005). Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 49: 4867-4875 [Abstract] [Full Text]  
  • Louie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., Drusano, G. L. (2005). Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity. Antimicrob. Agents Chemother. 49: 5058-5068 [Abstract] [Full Text]  
  • Kartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., Motyl, M. (2005). Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome. Antimicrob. Agents Chemother. 49: 3616-3623 [Abstract] [Full Text]  
  • Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  
  • Imai, J., Singh, G., Fernandez, B., Clemons, K. V., Stevens, D. A. (2005). Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 56: 166-171 [Abstract] [Full Text]  
  • Singh, G., Imai, J., Clemons, K. V., Stevens, D. A. (2005). Efficacy of Caspofungin against Central Nervous System Aspergillus fumigatus Infection in Mice Determined by TaqMan PCR and CFU Methods. Antimicrob. Agents Chemother. 49: 1369-1376 [Abstract] [Full Text]  
  • Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E. Jr., Douglas, C. M. (2005). Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob. Agents Chemother. 49: 721-727 [Abstract] [Full Text]  
  • MacCallum, D. M., Odds, F. C. (2004). Need for Early Antifungal Treatment Confirmed in Experimental Disseminated Candida albicans Infection. Antimicrob. Agents Chemother. 48: 4911-4914 [Abstract] [Full Text]  
  • Imai, J. K., Singh, G., Clemons, K. V., Stevens, D. A. (2004). Efficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 48: 4063-4066 [Abstract] [Full Text]  
  • Kowacs, P A, Monteiro de Almeida, S, Pinheiro, R L, Fameli, H, Piovesan, E J, Correia, A, Werneck, L C (2004). Central nervous system Aspergillus fumigatus infection after near drowning. J. Clin. Pathol. 57: 202-204 [Abstract] [Full Text]  
  • Reinoso-Martin, C., Schuller, C., Schuetzer-Muehlbauer, M., Kuchler, K. (2003). The Yeast Protein Kinase C Cell Integrity Pathway Mediates Tolerance to the Antifungal Drug Caspofungin through Activation of Slt2p Mitogen-Activated Protein Kinase Signaling. Eukaryot Cell 2: 1200-1210 [Abstract] [Full Text]  
  • Graybill, J. R., Bocanegra, R., Gonzalez, G. M., Najvar, L. K. (2003). Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 52: 656-662 [Abstract] [Full Text]  
  • Van Epps, H. L., Feldmesser, M., Pamer, E. G. (2003). Voriconazole Inhibits Fungal Growth without Impairing Antigen Presentation or T-Cell Activation. Antimicrob. Agents Chemother. 47: 1818-1823 [Abstract] [Full Text]  
  • Hossain, M. A., Reyes, G. H., Long, L. A., Mukherjee, P. K., Ghannoum, M. A. (2003). Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 51: 1427-1429 [Abstract] [Full Text]  
  • Graybill, J. R., Najvar, L. K., Gonzalez, G. M., Hernandez, S., Bocanegra, R. (2003). Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 51: 1373-1376 [Abstract] [Full Text]  
  • Letscher-Bru, V., Herbrecht, R. (2003). Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51: 513-521 [Abstract] [Full Text]  
  • Espinel-Ingroff, A. (2003). Evaluation of Broth Microdilution Testing Parameters and Agar Diffusion Etest Procedure for Testing Susceptibilities of Aspergillus spp. to Caspofungin Acetate (MK-0991). J. Clin. Microbiol. 41: 403-409 [Abstract] [Full Text]  
  • Walsh, T. J. (2002). Echinocandins -- An Advance in the Primary Treatment of Invasive Candidiasis. NEJM 347: 2070-2072 [Full Text]  
  • Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., Lopez-Ribot, J. L. (2002). In Vitro Activity of Caspofungin against Candida albicans Biofilms. Antimicrob. Agents Chemother. 46: 3591-3596 [Abstract] [Full Text]  
  • Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2002). The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro. Antimicrob. Agents Chemother. 46: 3001-3012 [Abstract] [Full Text]  
  • Ripeau, J.-S., Aumont, F., Belhumeur, P., Ostrosky-Zeichner, L., Rex, J. H., de Repentigny, L. (2002). Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro. Antimicrob. Agents Chemother. 46: 3096-3100 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., Perea, S., Coco, B. J., Patterson, T. F. (2002). Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 46: 2564-2568 [Abstract] [Full Text]  
  • Cenci, E., Mencacci, A., Spreca, A., Montagnoli, C., Bacci, A., Perruccio, K., Velardi, A., Magliani, W., Conti, S., Polonelli, L., Romani, L. (2002). Protection of Killer Antiidiotypic Antibodies against Early Invasive Aspergillosis in a Murine Model of Allogeneic T-Cell-Depleted Bone Marrow Transplantation. Infect. Immun. 70: 2375-2382 [Abstract] [Full Text]  
  • Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., Sable, C. A. (2002). Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases. Antimicrob. Agents Chemother. 46: 451-457 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., Walsh, T. J. (2002). Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia. Antimicrob. Agents Chemother. 46: 12-23 [Abstract] [Full Text]  
  • Arikan, S., Lozano-Chiu, M., Paetznick, V., Rex, J. H. (2002). In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp.. Antimicrob. Agents Chemother. 46: 245-247 [Abstract] [Full Text]  
  • Bowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2001). Quantitative PCR Assay To Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate. Antimicrob. Agents Chemother. 45: 3474-3481 [Abstract] [Full Text]  
  • (2001). Caspofungin. JWatch Infect. Diseases 2001: 9-9 [Full Text]  
  • Sullivan, K. M., Dykewicz, C. A., Longworth, D. L., Boeckh, M., Baden, L. R., Rubin, R. H., Sepkowitz, K. A. (2001). Preventing Opportunistic Infections After Hematopoietic Stem Cell Transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond. ASH Education Book 2001: 392-421 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»